2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC—A Closer Look at the Paradigm-Shifting Synergy of Safety, Efficacy, and Equitable Access
This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC.
Category
  • Oncology
Format
  • Podcasts
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 IPCE
  • 1.00 Participation
Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.
Category
  • Cardiology
Format
  • On-Demand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular
Category
  • Nephrology
Format
  • On-Demand
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Evolving Treatment Paradigms for Bladder Cancer: Expert Perspectives on the Latest Data
Join key thought leaders in the world of bladder cancer – Drs.
Category
  • Hematology
  • Oncology
Format
  • On-Demand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.
Category
  • Cardiology
Format
  • Podcasts
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy
Category
  • Oncology
Format
  • Video
  • On-Demand
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy
Category
  • Oncology
Format
  • Podcasts
  • On-Demand
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition
Category
  • Nephrology
Format
  • Podcasts
  • On-Demand
Credits
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation

Pages